[{"from": "human", "value": "Provide a description of this molecule. [C][C][Branch2][Branch1][Branch2][C][=Branch1][C][=O][N][Branch2][Ring1][#Branch2][C][=Branch1][C][=S][N][Ring1][#Branch1][C][=C][C][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][O][C][C@H1][Branch1][Ring1][C][O][O][C][=C][C][=Branch1][#Branch2][=C][Branch1][Branch1][C][=C][Ring1][=Branch1][C][#N][C][Branch1][C][F][Branch1][C][F][F][C]"}, {"from": "gpt", "value": "The molecule is an orally bioavailable androgen receptor (AR) antagonist with potential antineoplastic activity. Upon administration, rezvilutamide competitively binds to AR in target tissues, which both prevents androgen-induced receptor activation and facilitates the formation of inactive complexes that cannot be translocated to the nucleus. This prevents binding to and transcription of AR-responsive genes, inhibits the expression of genes that regulate prostate cancer cell proliferation, and may lead to an inhibition of cell growth of AR-expressing tumor cells. ARs are overexpressed in prostate cancer and play a key role in prostate cancer cell proliferation."}]